iktos
Entity
Description
  • Value proposition

    Artificial intelligence for new drug design

    We are Iktos. A start-up company specializing in the development of proprietary artificial intelligence technologies and software for ligand-based and structure-based de novo drug design focusing on multi parametric optimization.

    Our de novo design algorithm is based on deep generative models with reinforcement learning. It designs novel and easy to make compounds, optimized to meet a given multi-objective blueprint, with unprecedented speed, performance, and diversity.

    Please visit our webpage to know more about our products and offerings
    https://iktos.ai/products/

    artificial intelligence, medicinal chemistry, chemoinformatics, machine learning, deep learning, molecular modeling, CADD, MPO, de novo drug design, drug design, inverse-QSAR, QSAR, lead optimization, Robotics, and Automation

  • Original language

    Artificial intelligence for new drug design

    We are Iktos. A start-up company specializing in the development of proprietary artificial intelligence technologies and software for ligand-based and structure-based de novo drug design focusing on multi parametric optimization.

    Our de novo design algorithm is based on deep generative models with reinforcement learning. It designs novel and easy to make compounds, optimized to meet a given multi-objective blueprint, with unprecedented speed, performance, and diversity.

    Please visit our webpage to know more about our products and offerings
    https://iktos.ai/products/

Corporate interactions BETA
Corporate TypeTweets Articles
Région Ile de France
Région Ile de France
National and local authorities, Government Administration
Région Ile de France
National and local authorities, Government Administration 		Not capitalistic
Partnership
Event

24 May 2018


Similar entities
Last news
Show all articles
Social network dynamics